These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 162676)
21. Clinical aspects of the treatment of obesity by drugs: a review. Munro JF Int J Obes; 1979; 3(2):171-80. PubMed ID: 393645 [TBL] [Abstract][Full Text] [Related]
22. A double-blind trial of mazindol using a very low calorie formula diet. Baird IM; Howard AN Int J Obes; 1977; 1(3):271-8. PubMed ID: 363631 [TBL] [Abstract][Full Text] [Related]
23. Ephedrine as an anorectic: the story of the 'Elsinore pill'. Malchow-Møller A; Larsen S; Hey H; Stokholm KH; Juhl E; Quaade F Int J Obes; 1981; 5(2):183-7. PubMed ID: 7228474 [TBL] [Abstract][Full Text] [Related]
27. Clinical and basic aspects of an anorexiant, mazindol, as an antiobesity agent in Japan. Inoue S; Egawa M; Satoh S; Saito M; Suzuki H; Kumahara Y; Abe M; Kumagai A; Goto Y; Shizume K Am J Clin Nutr; 1992 Jan; 55(1 Suppl):199S-202S. PubMed ID: 1728834 [TBL] [Abstract][Full Text] [Related]
28. [Mazindol (AN-448): a new non-amphetamine anorectic in the treatment of exogenous obesity]. Delitala G; Alagna S; Masala A Clin Ter; 1977 Jun; 81(6):547-54. PubMed ID: 884939 [No Abstract] [Full Text] [Related]
29. The current status of antiobesity drugs. Galloway SM; Farquhar DL; Munro JF Postgrad Med J; 1984; 60 Suppl 3():19-26. PubMed ID: 6393107 [TBL] [Abstract][Full Text] [Related]
30. [Clinical use of mazindol in the treatment of essential obesity]. Guazzelli R; Piazzini M; Conti C; Papi L; Strazzulla G; Matassi L Clin Ter; 1987 Mar; 120(5):385-91. PubMed ID: 2953538 [No Abstract] [Full Text] [Related]
31. A multicentre study comparing mazindol and placebo in obese patients. Walker BR; Ballard IM; Gold JA J Int Med Res; 1977; 5(2):85-90. PubMed ID: 326596 [TBL] [Abstract][Full Text] [Related]
32. Effect of mazindol, d-amphetamine and diethylpropion on purine nucleotide binding to brown adipose tissue. Lupien JR; Bray GA Pharmacol Biochem Behav; 1986 Oct; 25(4):733-8. PubMed ID: 3786335 [TBL] [Abstract][Full Text] [Related]
33. [Effect of mazindol (teronac) on various hormonal indicators in children with simple obesity]. Komorowski JM; Zwaigzne-Raczyńska J; Owczarczyk I; Gołebiowska M; Zarzycki J Pediatr Pol; 1982 Apr; 57(4):241-6. PubMed ID: 6755371 [No Abstract] [Full Text] [Related]
34. A comparative trial of fenfluramine and diethylpropion in obese, hypertensive patients. Follows OJ Br J Clin Pract; 1971 May; 25(5):236-8. PubMed ID: 4931755 [No Abstract] [Full Text] [Related]
35. Double-blind cross-over evaluation of mazindol in the treatment of obese hypertensive patients. Miach PJ; Thomson W; Doyle AE; Louis WJ Med J Aust; 1976 Sep; 2(10):378-80. PubMed ID: 792640 [TBL] [Abstract][Full Text] [Related]
36. Short-term and long-term clinical evaluation of a non-amphetaminic anorexiant (mazindol) in the treatment of obesity. Enzi G; Baritussio A; Marchiori E; Crepaldi G J Int Med Res; 1976; 4(5):305-18. PubMed ID: 1028632 [TBL] [Abstract][Full Text] [Related]
37. A comparative trial of fenfluramine and diethylpropion inbesity. Silverstone JT; Cooper RM; Begg RR Br J Clin Pract; 1970 Oct; 24(10):423-5. PubMed ID: 4923926 [No Abstract] [Full Text] [Related]
38. Diethylpropion hydrochloride: an effective appetite suppressant. Bolding OT Curr Ther Res Clin Exp; 1974 Jan; 16(1):40-8. PubMed ID: 4203847 [No Abstract] [Full Text] [Related]
40. The effect of an anorectic agent (Mazindol) on control of obese diabetics. Sanders M; Breidahl H Med J Aust; 1976 Oct; 2(15):576-7. PubMed ID: 994969 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]